Analysts say Merck's latest earnings report shows the company's turnaround plan is working, aided by cost-cutting and sales of new medicines, such as its Gardasil vaccine against cervical cancer. Merck also reported it added $210 million to its reserve for defending against Vioxx lawsuits, which now number 26,950.

Related Summaries